BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 23811235)

  • 21. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
    Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
    Yoon H; Kwak Y; Choi S; Cho H; Kim ND; Sim T
    J Med Chem; 2016 Jan; 59(1):358-73. PubMed ID: 26652860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
    Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
    Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
    Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
    Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of
    Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
    ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural study of ponatinib in inhibiting SRC kinase.
    Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
    Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RET inhibition: implications in cancer therapy.
    Borrello MG; Ardini E; Locati LD; Greco A; Licitra L; Pierotti MA
    Expert Opin Ther Targets; 2013 Apr; 17(4):403-19. PubMed ID: 23461584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
    Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
    J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
    Plaza-Menacho I; Mologni L; Sala E; Gambacorti-Passerini C; Magee AI; Links TP; Hofstra RM; Barford D; Isacke CM
    J Biol Chem; 2007 Oct; 282(40):29230-40. PubMed ID: 17664273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
    Verbeek HH; Alves MM; de Groot JW; Osinga J; Plukker JT; Links TP; Hofstra RM
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E991-5. PubMed ID: 21470995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.